Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX-02 MAD Study in Healthy Volunteers
NCT03309605Phase 1Completed
- Start
- Oct 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) and nephropathic cystinosis comparing Placebo Comparator Arm with ELX-02 (2 arms). Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to 24 Hours, Maximum Plasma Concentration at Day 29 and 8 more. Started Oct 2017; status: completed.
02
Drugs
exaluren
03
Conditions
cystic fibrosis (CF)nephropathic cystinosis
Beyond the preview
Go deeper on NCT03309605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309605.